Controlled porosity osmotic pump system for the delivery of diclofenac sodium: In-vitro and in-vivo evaluation

Pharmaceutical Development and Technology

Volumn 19, Issue 6, 2014, Pages 681-691

  Emara, Laila H ^a   Taha, Nesrin F ^a   El Ashmawy, Ahmed A ^a   Raslan, Hala M ^a   Mursi, Nadia M ^b  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Comparative bioavailability; Controlled porosity osmotic pump; Diclofenac sodium; Porosigen; Voltaren Retard

Indexed keywords

CAPTOPRIL; DICLOFENAC; GLIPIZIDE; HYDROXYPROPYLMETHYLCELLULOSE; LACTOSE; MACROGOL 400; MANNITOL; MICROCRYSTALLINE CELLULOSE; POLYMER; PROPRANOLOL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED POROSITY OSMOTIC PUMP TABLET; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG RELEASE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TABLET FORMULATION; TABLET THICKNESS; TIME TO MAXIMUM PLASMA CONCENTRATION; VISCOSITY;

ABSORPTION; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DICLOFENAC; DRUG DELIVERY SYSTEMS; HUMANS; MALE; OSMOSIS; POLYMERS; POROSITY; TABLETS; VISCOSITY;

EID: 84899874159     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2013.823990     Document Type: Article

References (76)

1. Salsa T, Veiga F, Pina ME. Oral controlled-release dosage forms. I. Cellulose ether polymers in hydrophilic matrices. Drug Dev Ind Pharm 1997;23:929-938.
2. Verma RK, Mishra B. Studies on formulation and evaluation of oral osmotic pump of nimesulide. Pharmazie 1999;54:74-75.
3. Verma RK, Mishra B, Garg S. Osmotically controlled oral drug delivery. Drug Dev Ind Pharm 2000;26:695-708.
4. Ramakrishna N, Mishra B. Design and evaluation of osmotic pump tablets of naproxen sodium. Pharmazie 2001;56:958-962.
5. Ramakrishna N, Mishra B. Plasticizer effect and comparative evaluation of cellulose acetate and ethylcellulose-HPMC combination coatings as semipermeable membranes for oral osmotic pumps of naproxen sodium. Drug Dev Ind Pharm 2002;28:403-412.
6. Liu L, Wang J, Zhu S. Delivery of prazosin hydrochloride from osmotic pump system prepared by coating the core tablet with an indentation. Drug Deliv 2007;14:219-224.
7. Prabakaran D, Singh P, Kanaujia P, et al. Modified push-pull osmotic system for simultaneous delivery of theophylline and salbutamol: development and in vitro characterization. Int J Pharm 2004;284:95-108.
8. Theeuwes F. Elementary osmotic pump. J Pharm Sci 1975;64: 1987-1991.
9. Santus G, Baker RW. Osmotic drug delivery: a review of the patent literature. J Contr Rel 1995;35:1-21.
10. Liu L, Ku J, Khang G, et al. Nifedipine controlled delivery by sandwiched osmotic tablet system. J Contr Rel 2000;68:145-156.
11. Verma RK, Krishna DM, Garg S. Formulation aspects in the development of osmotically controlled oral drug delivery systems. J Contr Rel 2002;79:7-27.
12. Theeuwes F. Osmotic system for delivering selected beneficial agents having varying degrees of solubility. 1978: US Patent No. 4,111,201.
13. Herbig SM, Cardinal JR, Korsmeyer RW, Smith KL. Asymmetricmembrane tablet coatings for osmotic drug delivery. J Contr Rel 1995;35:127-136.
14. Thombre AG, Cardinal JR, DeNoto AR, et al. Asymmetric membrane capsules for osmotic drug delivery. J Contr Rel 1999; 57:55-73.
15. Thombre AG, Appel LE, Chidlaw MB, et al. Osmotic drug delivery using swellable-core technology. J Contr Rel 2004;94:75-89.
16. Speers M, Bonnano C. Economic aspects of controlled drug delivery. Encyclopedia of controlled drug delivery. New York: Wiley; 1999:341-347.
17. Haslam JL, Rork GS. Controlled porosity osmotic pump. 1989: US Patent No. 4,880,631.
18. Zentner GM, Rork GS, Himmelstein KJ. 1990: US Patent No. 4968507.
19. Makhija SN, Vavia PR. Controlled porosity osmotic pump-based controlled release system of pseudoephedrine. J Contr Rel 2003;89: 5-18.
20. Thombre AG, Zentner GM, Himmelstein KJ. Mechanism of water transport in controlled porosity osmotic devices. J Membr Sci 1989; 40:279-310.
21. Zentner GM, MeClelland GA, Sutton SC. Controlled porosity solubility and resin-modulated osmotic drug delivery systems for release of diltiazem hydrochloride. J Contr Rel 1991;16:237-244.
22. Lewis AJ, Frust DW. Nonsteroidal anti-inflammatory drugs: mechanisms and clinical use. New York: Marcel Dekker; 1987.
23. Zuckner J. International experience with diclofenac in rheumatoid arthritis. Am J Med 1986;80:39-42.
24. Kantor TG. Use of diclofenac in analgesia. Am J Med 1986;80: 64-69.
25. Lundstam S, Leissner KH, Wablender LH. Prostaglandin-synthetase inhibition with diclofenac sodium in treatment of renal colic: comparison with use of a narcotic analgesic. Lancet 1982;1: 1096-1097.
26. Shoutakis VA, Carter CA, Mickle TR, et al. Review of diclofenac and evaluation of its place in therapy as a nonsteroidal antiinflammatory agent. Drug Intel Clin Pharm 1988;22:850-859.
27. Garcia-Encina G, Torres D, Seijo B, Vila Jato JL. Formulation and in vitro evaluation of HPMCP-microencapsulated drug-resin complexes for sustained release of diclofenac. Int J Pharm 1995;121: 239-243.
28. Nokhodchi A, Farid DJ, Najafi M, Adrangui M. Studies on controlled-release formulations of diclofenac sodium. Drug Dev Ind Pharm 1997;23:1019-1023.
29. Rani M, Mishra B. Comparative in vitro and in vivo evaluation of matrix, osmotic matrix, and osmotic pump tablets for controlled delivery of diclofenac sodium. AAPS Pharmsci 2004;5:153-159.
30. Rani M, Surana R, Sankar C, Mishra B. Development and biopharmaceutical evaluation of osmotic pump tablets for controlled delivery of diclofenac sodium. Acta Pharm 2003;53:263-273.
31. Rani M, Surana R, Sankar C, Mishra B. Formulation and biopharmaceutical evaluation of osmotic matrix tablets of diclofenac sodium. Drug Deliv 2004;11:263-270.
32. Mishra B, Sankar C, Dilip C, et al. Osmotically controlled diclofenac sodium tablets: membrane and osmogens effects. Der Pharmacia Letter 2010;2:21-27.
33. Edavalath S, Shivanand K, Prakasam K, et al. Formulation developement and optimization of controlled porosity osmotic pump tablets of diclofenac sodium. Int J Pharm Pharm Sci 2011;3: 80-87.
34. Emara LH, Taha NF, Badr RM, Mursi NM. Development of an osmotic pump system for controlled delivery of diclofenac sodium. Drug Discov Therap 2012;6:269-277.
35. Emara LH, Taha NF, Mursi NM. Investigation of the effect of different flow-through cell designs on the release of diclofenac sodium SR tablets. Dissol Technol 2009;May:23-31.
36. Nama M, Gonugunta CS, Reddy Veerareddy P. Formulation and evaluation of gastroretentive dosage forms of clarithromycin. APPS PharmSciTech 2008;9:231-237.
37. Samani SM, Adrangui RJ, Siahi-Shadbad MR, Nokhodchi A. An approach to controlled-release dosage form of propranolol hydrochloride. Drug Dev Ind Pharm 2000;26:91-94.
38. Altinkaya SA, Yenal H. In vitro drug release rates from asymmetricmembrane tablet coatings: prediction of phase-inversion dynamics. Biochem Eng J 2006;28:131-139.
39. Moore JW, Flanner HH. Mathematical comparison of curves with an emphasis on in-vitro dissolution profiles. Pharm Tech 1996;20: 64-74.
40. Darwish IA, El-Massik MA, Hassan EE, El-Khordagui LK. Assessment of a hydroalcoholic surfactant solution as a medium for the dissolution testing of phenytoin. Int J Pharm 1996;140: 25-32.
41. El-Massik MA, Darwish IA, Hassan EE, El-Khordagui LK. Development of a dissolution medium for glibenclamide. Int J Pharm 1996;140:69-76.
42. Emara LH, Taha NF, El-Ashmawy AA, et al. A rapid and sensitive bioanalytical HPLC method for determining diclofenac sodium in human plasma for bioequivalence studies. J liq Chromatogr Rel Tech 2012;35:2203-2216.
43. Guidance for Industry: Bioanalytical Method Validation, US Department of Health and Human Services, FDA (2001), Center of Drug Evaluation and Research (CDER), Rockville, MD, USA. Available from: http://www.fda.gov/downloads/Drugs/ Guidance ComplianceRegulatoryInformation/Guidances/ucm070107.pdf [last accessed 22 April 2010].
44. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker Inc; 1982.
45. General Guidance, Statistical Procedures for Bioequivalence Studies Using a Standard Two-Treatment Crossover Design. Available from: http://www. pharmacopeia.cn/v29240/usp29nf24s0-c1090s2.html [last accessed 10 March 2013].
46. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations. US Department of Health and Human Services, FDA (2001), Center for Drug Evaluation and Research (CDER), Rockville, MD, USA, 2003. Available from: http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070124. pdf [last accessed 10 March 2013].
47. Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Rockville, MD, USA, 2001. Available from http://www.fda.gov/downloads/Drugs/Guidances/ ucm070244.pdf [last accessed 10 March 2013].
48. Razaghi AM, Schwartz JB. Investigation of cyclobenzaprine hydrochloride from oral osmotic delivery systems containing a watersoluble polymer. Drug Dev Ind Pharm 2002;28:631-639.
49. Xu L, Li S, Sunada H. Preparation and evaluation in vitro and in vivo of captopril elementary osmotic pump tablets. Asian J Pharm Sci 2006;1:236-245.
50. Shokri J, Ahmadi P, Rashidi P, et al. Swellable elementary osmotic pump (SEOP): an effective device for delivery of poorly watersoluble drugs. Eur J Pharm Biopharm 2008;68:289-297.
51. Gan Y, Pan W, Wei M, Zhang R. Cyclodextrin complex osmotic tablet for glipizide delivery. Drug Dev Ind Pharm 2002;28: 1015-1021.
52. Wang C, Chen F, Li JZ, et al. A novel osmotic pump tablet using core of drug - resin complexes for time controlled delivery system. Yakugaku Zasshi: Pharm Soc Japan 2008;128:773-782.
53. Kamba M, Seta Y, Kusai A, et al. (2000). A unique dosage form to evaluate the mechanical destructive force in the gastrointestinal tract. Int J Pharm 2000;208:61-70.
54. Kamba M, Seta Y, Kusai A, Nishimura K. Evaluation of the mechanical destructive force in the stomach of dog. Int J Pharm 2001;228:209-217.
55. Kanagale P, Lohray BB, Misra A, et al. Formulation and optimization of porous osmotic pump-based controlled release system of oxybutynin. AAPS PharmSciTech 2007;8:El3-El9 (Article 53).
56. Yakubu R, Peh KK, Tan YT. Design of a 24-hour controlled porosity osmotic pump system containing PVP: formulation variables. Drug Dev Ind Pharm 2009;35:1430-1438.
57. Cheng X, Sun M, Gao Y, et al. Design and evaluation of osmotic pump-based controlled release system of ambroxol hydrochloride. Pharm Dev Technol 2011;16:392-399.
58. Bi Y, Mao S, Gan L, et al. A controlled porosity osmotic pump system with biphasic release of theophylline. Chem Pharm Bull (Tokyo) 2007;55:1574-1580.
59. Saul Levinson R, Mitan SJ, Steinmetz JI, et al. An open-label, twoperiod, crossover study of the systemic bioavailability in healthy women of clindamycin phosphate from two vaginal cream formulations. Clin Ther 2005;27:1894-1900.
60. Metzler CM. Statistical criteria. In: Welling PG, Tse FLS, Dighe SV, eds. Pharmaceutical bioequivalence. New York: Marcel Dekker, Inc; 1991:35-66.
61. Emara LH, El-Menshawi BS, Estefan MY. In vitro - in vivo correlation and comparative bioavailablity of vincamine in prolonged- release preparations. Drug Dev Ind Pharm 2000;26:243-251.
62. Hamoudi MC, Bourasset F, Domergue-Dupont V, et al. Formulations based on alpha cyclodextrin and soybean oil: an approach to modulate the oral release of lipophilic drugs. J Contr Rel 2012;161:861-867.
63. Marzo A. Open questions on bioequivalence: an updated reappraisal. Curr Clin Pharmacol 2007;2:179-189.
64. Fourtillan JB, Dubourg D. Pharmacokinetic study of piroxicam in healthy man after administration of a single dose equal to 20 mg, by the oral route. Therapie 1983;38:163-170.
65. Brogden RN, Heel RC, Speight TM, Avery GS. Piroxicam. A reappraisal of its pharmacology and therapeutic efficacy. Drugs 1984;28:292-323.
66. Balan G, Timmins P, Greene DS, Marathe PH. In-vitro - in-vivo correlation models for glibenclamide after administration of metformin/glibenclamide tablets to healthy human volunteers. J Pharm Pharmacol 2000;52:831-838.
67. Ikegami H, Shima K, Tanaka A, et al. Interindividual variation in the absorption of glibenclamide in man. Acta Endocrinol (Copenh) 1986;111:528-532.
68. Parquet M, Metman EH, Raizman A, et al. Bioavailability, gastrointestinal transit, solubilization and faecal excretion of ursodeoxycholic acid in man. Eur J Clin Invest 1985;15: 171-178.
69. Chan KK, Mojaverian P, Ziehmer BA, John VA. Application of radiotelemetric technique in evaluating diclofenac sodium absorption after oral administration of various dosage forms in healthy volunteers. Pharm Res 1990;7:1026-1032.
70. Terhaag B, Gramatte T, Hrdlcka P, et al. The influence of food on the absorption of diclofenac as a pure substance. Int J Clin Pharmacol Ther Toxicol 1991;29:418-421.
71. Marzo A, Dal Bo L, Verga F, et al. Pharmacokinetics of diclofenac after oral administration of its potassium salt in sachet and tablet formulations. Arzneimittelforschung 2000;50:43-47.
72. Macia MA, Frias J, Carcas AJ, et al. Comparative bioavailability of a dispersible formulation of diclofenac and finding of double plasma peaks. Int J Clin Pharmacol Ther 1995;33:333-339.
73. Reiner V, Reiner A, Reiner G, Conti M. Increased absorption rate of diclofenac from fast acting formulations containing its potassium salt. Arzneimittelforschung 2001;51:885-890.
74. Su S-F, Chou C-H, Kung C-F, Huang J-d. In vitro and in vivo comparison of two diclofenac sodium sustained release oral formulations. Int J Pharm 2003;260:39-46.
75. Bettini R, Giordano F, Donini C, et al. Swelling force development as a result of hydrate formation in diclofenac sodium or nitrofurantoin tablets. STP Pharma Sci 2000;10:335-339.
76. Marzo A, Reiner V. (2004). Open questions on bioequivalence: the case of multiple peak phenomenon. J Pharm Pharmacol 2004;56: 281-282.